Exelixis, Inc. (NASDAQ:EXEL) Analyst Estimates
Exelixis, Inc. (NASDAQ:EXEL) stock is presently standing at about $21.85 and lots of equity research firms seem to have a target price set on the stock. The median one-year price target of 4 analysts covering the company is $26.00, which suggests the stock could still rise over 16 percent. The highest analyst price target is $26.00, which implies a rally of 81 percent. And a quick view of analyst notes show that 3 are rating the stock a buy while 3 rate EXEL a strong buy. There are 0 equity research firms advocating a Hold and 0 consider it Sell.
Stifel analysts provided their view on Exelixis, Inc. (NASDAQ:EXEL) recently. The rating firm issued a Hold rating to this company in a research note released on Feb 28, 2017. Deutsche Bank analysts disclosed their opinion on Exelixis, Inc. (NASDAQ:EXEL) recently. The rating firm gave a Buy rating to this stock in a research note published on Nov 03, 2016. According to a research note disclosed on Oct 10, 2016, analysts at Piper Jaffray have upped their rating on these shares from Neutral to Overweight.
Exelixis, Inc. (NASDAQ:EXEL) Transactions Roundup
Several insiders were part of recent insider activity for the stock. Its Director MARCHESI VINCENT T sold 40,000 company shares for 879200, in a transaction on 2017-03-10. Following the transaction, the Director is left with a stake of 120,070 shares, currently valued at $2623530. Meanwhile, President and CEO MORRISSEY MICHAEL sold 200,000 shares worth $4544000, through a transaction dated 2017-03-06. Following the completion of the transaction, the insider is left with a stake of 249,523 shares, amounting $5452077.55. EXEL EVP and General Counsel Hessekiel Jeffrey also sold 100,000 shares, at a stock price of $23.04. This transaction occurred on 2017-03-03 totals $2304000. After this transaction, the insider’s stake stands at 246,617 shares, with a market value of $5388581.
Executives hold 1.69 percent of the stock. Dr. George A. Scangos,PhD is one of the biggest insider owners in Exelixis, Inc. (NASDAQ:EXEL), according to U.S. Securities and Exchange Commission (SEC) filings. The insider owns 1,463,648 shares which have current market value of around $31980708.8.Dr. Stelios Papadopoulos,PhD is another major inside shareholder in the company. The insider owns 1,228,471 shares as of 0.42%, currently worth $26842091.35. Dr. Lance Willsey,M.D. is ranked as third insider holder of the stock. This insider holds 568,273 shares with a market value around $12416765.05 as of recent close.
Exelixis, Inc. (NASDAQ:EXEL) Earnings Outlook
In Exelixis, Inc. (NASDAQ:EXEL)’s latest quarter, EPS moved to $0.12 from $-0.04 in preceding quarter and revenues reached at $77.58M compared to $62.19M. Analysts had expected Exelixis, Inc. (NASDAQ:EXEL) to post net income of about $-0.01 per share on $66.50M in revenue. Looking ahead, analysts on average predict that earnings for the current quarter would come in in the range of $-0.02 to $0.01. That is compared with the $-0.27 in EPS it reported during the same period a year ago.